NOT trade ideas
$NVS $PFE $AZN coming aroundNovartis RSI is the most oversold it has been in 9 years
It now sits on a strong support with a range of just 2 dollars below current levels
Fib retracement of 1.618 takes this to 74 dollars before the turnaround
All of pharma has taken a hit over the last 4 weeks without real justification.
I believe all pop up after they announce earnings throughout the week
Novartis almost a buyPharmaceutical stocks represents a defensive asset when a positive market cycle is about to finish or when it is foreseen a cycle less positive than the previous one. In such context pharma stocks should have an advantage because of inelastic demand for such goods.
Novartis ($NVS,$NOVN) is one of the candidate to break up as the price is moving in a triangle since 2015. the stock doesn't not have an high volatility as other stocks but is one of the main represented of INDEX STOCK HEALTH CARE. There are nice technical indications on the chart that a breakout might happen in the next weeks. At the moment I am expecting a price pullback, where at the end it will be possible to go for an entry long.
Conclusions
At the moment price is consolidating and some other days to reduce RSI value will be needed. It's possible either to open positions at the end of the pullback or when price breaks out the downtrend (2015). Possibility to have it in CHF or $.
Novartis - Long planThe price got out of its ranging bound. The lagging span broke the Kijun and had just bounced on the range rectangle before. We may expect the price to lateralize a bit before the earnings and then, if they are positive, to see an uptrend that would make it reach the higher part of the cloud. A retracement after benefits are taken would provide a good entry point for a long, ideally supported by the SSB and with a target given by a flat Kijun level, 80 or 82.
RSI is bullish and if it manages to stay above 60, the scenario would have more weight.
